Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review
Open Access
- 27 May 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Infectious Diseases and Therapy
- Vol. 9 (3), 435-449
- https://doi.org/10.1007/s40121-020-00303-8
Abstract
The emergence of SARS-CoV-2/2019 novel coronavirus (COVID-19) has created a global pandemic with no approved treatments or vaccines. Many treatments have already been administered to COVID-19 patients but have not been systematically evaluated. We performed a systematic literature review to identify all treatments reported to be administered to COVID-19 patients and to assess time to clinically meaningful response for treatments with sufficient data. We searched PubMed, BioRxiv, MedRxiv, and ChinaXiv for articles reporting treatments for COVID-19 patients published between 1 December 2019 and 27 March 2020. Data were analyzed descriptively. Of the 2706 articles identified, 155 studies met the inclusion criteria, comprising 9152 patients. The cohort was 45.4% female and 98.3% hospitalized, and mean (SD) age was 44.4 years (SD 21.0). The most frequently administered drug classes were antivirals, antibiotics, and corticosteroids, and of the 115 reported drugs, the most frequently administered was combination lopinavir/ritonavir, which was associated with a time to clinically meaningful response (complete symptom resolution or hospital discharge) of 11.7 (1.09) days. There were insufficient data to compare across treatments. Many treatments have been administered to the first 9152 reported cases of COVID-19. These data serve as the basis for an open-source registry of all reported treatments given to COVID-19 patients at www.CDCN.org/CORONA. Further work is needed to prioritize drugs for investigation in well-controlled clinical trials and treatment protocols.Keywords
This publication has 48 references indexed in Scilit:
- Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell linesBiochemical and Biophysical Research Communications, 2005
- Use of convalescent plasma therapy in SARS patients in Hong KongEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compoundsJournal of Clinical Virology, 2004
- Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patientsClinical Microbiology & Infection, 2004
- Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findingsThorax, 2004
- Do Men Have a Higher Case Fatality Rate of Severe Acute Respiratory Syndrome than Women Do?American Journal of Epidemiology, 2004
- Chicken Interferon Type I Inhibits Infectious Bronchitis Virus Replication and Associated Respiratory IllnessJournal of Interferon & Cytokine Research, 2001
- Prevention of Experimental Coronavirus Colds with Intranasal -2b InterferonThe Journal of Infectious Diseases, 1986
- Phase variation in the modulation of the human immune responseImmunology Today, 1983